DK3281952T3 - Antigen, der er forbundet med reumatoid artritis - Google Patents

Antigen, der er forbundet med reumatoid artritis Download PDF

Info

Publication number
DK3281952T3
DK3281952T3 DK17189028.8T DK17189028T DK3281952T3 DK 3281952 T3 DK3281952 T3 DK 3281952T3 DK 17189028 T DK17189028 T DK 17189028T DK 3281952 T3 DK3281952 T3 DK 3281952T3
Authority
DK
Denmark
Prior art keywords
rheumatoid arthritis
antigen associated
antigen
rheumatoid
arthritis
Prior art date
Application number
DK17189028.8T
Other languages
Danish (da)
English (en)
Inventor
Manuela Kaspar
Kathrin Schwager
Eveline Trachsel
Original Assignee
Philogen Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philogen Spa filed Critical Philogen Spa
Application granted granted Critical
Publication of DK3281952T3 publication Critical patent/DK3281952T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK17189028.8T 2007-10-30 2008-10-27 Antigen, der er forbundet med reumatoid artritis DK3281952T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98360607P 2007-10-30 2007-10-30
EP08844563.0A EP2209805B1 (en) 2007-10-30 2008-10-27 An antigen associated with rheumatoid arthritis

Publications (1)

Publication Number Publication Date
DK3281952T3 true DK3281952T3 (da) 2020-08-03

Family

ID=40282320

Family Applications (2)

Application Number Title Priority Date Filing Date
DK17189028.8T DK3281952T3 (da) 2007-10-30 2008-10-27 Antigen, der er forbundet med reumatoid artritis
DK08844563.0T DK2209805T3 (en) 2007-10-30 2008-10-27 Antigen associated with rheumatoid arthritis

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK08844563.0T DK2209805T3 (en) 2007-10-30 2008-10-27 Antigen associated with rheumatoid arthritis

Country Status (18)

Country Link
US (4) US8222377B2 (enExample)
EP (3) EP3783019A1 (enExample)
JP (3) JP5106635B2 (enExample)
KR (3) KR102002739B1 (enExample)
CN (2) CN101918443B (enExample)
AU (1) AU2008317941B2 (enExample)
BR (1) BRPI0818272B8 (enExample)
CA (1) CA2704296C (enExample)
DK (2) DK3281952T3 (enExample)
ES (2) ES2646228T3 (enExample)
HU (2) HUE037036T2 (enExample)
MX (1) MX2010004726A (enExample)
NO (1) NO2209805T3 (enExample)
PL (2) PL3281952T3 (enExample)
PT (2) PT3281952T (enExample)
RU (2) RU2486198C2 (enExample)
SI (2) SI3281952T1 (enExample)
WO (1) WO2009056268A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070084556A1 (en) 2005-10-14 2007-04-19 Langseder Neal E Method of applying a label to a squeeze tube
EP2653478B1 (en) * 2007-04-02 2016-10-05 Philogen S.p.A. A novel antigen associated with the neovasculature of tumour metastases
US10202442B2 (en) 2007-07-25 2019-02-12 Philogen S.P.A. Antigen associated with lung cancers and lymphomas
CN101918443B (zh) 2007-10-30 2013-07-17 菲洛根股份公司 一种与类风湿性关节炎相关的抗原
EP2379116B1 (en) 2009-01-07 2015-08-26 Philogen S.p.A. Antigens associated with endometriosis
US8679488B2 (en) 2009-08-05 2014-03-25 Philogen S.P.A. Targeting of bone marrow neovasculature
EP2736535B1 (en) * 2011-07-27 2018-10-17 Philogen S.p.A. Il-12 immunoconjugate
PE20150645A1 (es) * 2012-08-08 2015-05-11 Roche Glycart Ag Proteinas de fusion de interleuquina 10 y usos de las mismas
TWI499426B (zh) * 2012-09-27 2015-09-11 Philogen Spa 與發炎性腸病有關之抗原
ES2743423T3 (es) 2012-10-03 2020-02-19 Philogen Spa Conjugado de anticuerpos para su uso en el tratamiento de una enfermedad inflamatoria intestinal
RU2016135788A (ru) * 2014-02-06 2018-03-07 Ф.Хоффманн-Ля Рош Аг Иммуноконъюгаты интерлейкина 10
GB201507908D0 (en) 2015-05-08 2015-06-24 Philogen Spa IL2 and TNF immunoconjugates
EP3322719B1 (en) 2015-07-16 2019-12-18 Philogen S.p.A. Il22 immunoconjugates
US20190309060A1 (en) 2016-01-15 2019-10-10 Philogen S.P.A. Intestinal antigens for pharmacodelivery applications
JP2017197558A (ja) * 2017-06-07 2017-11-02 フィロゲン エスピーエー 炎症性腸疾患に関連する抗原
CA3065153C (en) 2017-06-07 2023-09-05 Philogen S.P.A. Vascular endothelial growth factor/anti-fibronectin antibody fusion proteins
CN113811549A (zh) 2019-02-21 2021-12-17 Xencor股份有限公司 非靶向和靶向性il-10 fc融合蛋白
US10858412B2 (en) * 2019-03-06 2020-12-08 Deka Biosciences, Inc. Antibody variable domain regions fused to IL-10 variant molecules
WO2020249757A1 (en) 2019-06-14 2020-12-17 Philogen S.P.A Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sushi domain of interleukin-15 receptor alpha
CA3186753A1 (en) 2020-07-20 2022-01-27 John Mumm Dual cytokine fusion proteins comprising il-10
EP4185615A1 (en) 2020-07-22 2023-05-31 Philogen S.p.A. Treatment of pulmonary hypertension
CN113480636B (zh) * 2021-06-23 2023-11-03 烟台科瑞斯生物技术有限责任公司 重组人纤连蛋白及其制备、活性测定和稳定性实验方法
US20250197485A1 (en) 2022-03-17 2025-06-19 Universitätsklinikum Jena Anti-ED-A Antibodies for the Treatment of Pulmonary Hypertension
WO2026003203A1 (en) 2024-06-27 2026-01-02 Philogen S.P.A. Combination of an immunocytokine comprising targeted il2 and a jak inhibitor

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IT1217724B (it) 1988-05-26 1990-03-30 Ist Naz Ric Sul Cancro Anticorpo monoclonale specifico per una sequenza di fibronettina espressa in cellule trasformate ibridoma secernente tale anticorpo e impiego dell'anticorpo monoclonale per la diagnosi di tumori
US5420012A (en) 1989-05-08 1995-05-30 Locus Genex Oy Method for the detection of reactive conditions
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
GB9206318D0 (en) 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
EP0580859A4 (en) * 1991-03-26 1994-09-14 Otsuka Pharma Co Ltd Anti-eda monoclonal antibody
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
US5962255A (en) 1992-03-24 1999-10-05 Cambridge Antibody Technology Limited Methods for producing recombinant vectors
US6492160B1 (en) 1991-05-15 2002-12-10 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US5872215A (en) 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
US5644033A (en) 1992-12-22 1997-07-01 Health Research, Inc. Monoclonal antibodies that define a unique antigen of human B cell antigen receptor complex and methods of using same for diagnosis and treatment
AU6098994A (en) 1993-01-27 1994-08-15 Duke University Methods and agents for the diagnosis and treatment of rheumatoid arthritis
US6054312A (en) * 1997-08-29 2000-04-25 Selective Genetics, Inc. Receptor-mediated gene delivery using bacteriophage vectors
DK1137941T4 (da) 1998-12-10 2014-01-06 Brystol Myers Squibb Company Protein-scaffolds til antistof-mimetika og andre bindingsproteiner
ATE526039T1 (de) 2000-02-24 2011-10-15 Philogen Spa Zusammensetzungen und verfahren zur behandlung von angiogenese in pathologischen schädigungen
CA2404919A1 (en) * 2000-04-06 2002-10-01 Kyowa Hakko Kogyo Co. Ltd. Diagnostic and therapeutic agents for rheumatoid arthritis
AU5867901A (en) 2000-05-04 2001-11-12 Philogen S.R.L. Method for detecting tumors
EP1381629B1 (de) 2000-09-07 2008-09-10 Bayer Schering Pharma Aktiengesellschaft REZEPTOR DER EDb-FIBRONEKTIN-DOMÄNE (II)
US6780594B2 (en) 2000-09-25 2004-08-24 Schering Aktiengesellschaft Method for in vitro diagnosis of endometriosis
IT1317108B1 (it) 2000-12-06 2003-05-26 Philogen Srl Processo per la selezione di frammenti anticorporali anti-angiogenesi,frammenti anticorpali anti-angiogenesi cosi' ottenuti e loro uso.
US20020187100A1 (en) 2000-12-21 2002-12-12 David Rizzieri Anti-tenascin monoclonal antibody therapy for lymphoma
EP1224943A1 (en) 2001-01-19 2002-07-24 Crucell Holland B.V. Fibronectin as a tumor marker detected by phage antibodies
GB0209896D0 (en) 2002-04-30 2002-06-05 Molmed Spa Conjugate
WO2004000216A2 (en) 2002-06-21 2003-12-31 Duke University Anti-tenascin antibody fragments and minibodies for treatment of lymphoma
EP1572131B1 (en) * 2002-10-08 2016-07-06 Immunomedics, Inc. Antibody therapy
CA2508831C (en) 2002-12-13 2012-05-01 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
US20040202666A1 (en) 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
WO2004094612A2 (en) 2003-04-22 2004-11-04 A & G Pharmaceutical, Inc. Cancer specific monoclonal antibodies
WO2005009366A2 (en) 2003-07-24 2005-02-03 Cornell Research Foundation, Inc. Restoring vascular function
US8038983B2 (en) 2003-07-29 2011-10-18 Immunomedics, Inc. Fluorinated carbohydrate conjugates
EA011859B9 (ru) 2004-01-05 2013-07-30 Емд Лексиген Ресерч Сентер Корп. Соединения для адресной доставки препарата к ткани или органу-мишени
CA2575675A1 (en) 2004-07-30 2006-03-09 Adeza Biomedical Corporation Oncofetal fibronectin as a marker for disease and other conditions and methods for detection of oncofetal fibronectin
US7785591B2 (en) 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
EA013537B1 (ru) 2004-11-09 2010-06-30 Филоген Спа Антитела к тенасцину-с человека и их применение
EP2364995A1 (en) * 2004-12-23 2011-09-14 Molmed SpA Conjugation product
ES2341126T3 (es) * 2005-05-11 2010-06-15 Philogen S.P.A. Proteina de fusion del anticuerpo l19 contra fibronectina ed-b e interleucina 12.
EP1893244A4 (en) 2005-06-23 2009-06-24 Univ Emory AGENTS FOR IMAGING
JP2009535372A (ja) 2006-05-03 2009-10-01 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 抗ｅｄｂフィブロネクチンドメイン抗体ｌ１９−ｓｉｐ及び抗−ｅｇｆｒ−抗体の組合せ
ES2606490T3 (es) * 2006-05-08 2017-03-24 Philogen S.P.A. Citocinas dirigidas por anticuerpos para terapia
EP2653478B1 (en) * 2007-04-02 2016-10-05 Philogen S.p.A. A novel antigen associated with the neovasculature of tumour metastases
US10202442B2 (en) 2007-07-25 2019-02-12 Philogen S.P.A. Antigen associated with lung cancers and lymphomas
KR101781638B1 (ko) 2007-07-25 2017-09-25 필로겐 에스.피.에이. 종양 전이의 신생혈관과 관련된 피브리노겐의 ｅｄ-ａ 항원
CN101918443B (zh) 2007-10-30 2013-07-17 菲洛根股份公司 一种与类风湿性关节炎相关的抗原
EP2379116B1 (en) 2009-01-07 2015-08-26 Philogen S.p.A. Antigens associated with endometriosis
EP2379117A2 (en) 2009-01-07 2011-10-26 Philogen S.p.A. Cancer treatment
EP2621535A1 (en) 2010-09-29 2013-08-07 Philogen S.p.A. Thiazolidine linker for the conjugation of drugs to antibodies
EP2736535B1 (en) 2011-07-27 2018-10-17 Philogen S.p.A. Il-12 immunoconjugate
ES2743423T3 (es) 2012-10-03 2020-02-19 Philogen Spa Conjugado de anticuerpos para su uso en el tratamiento de una enfermedad inflamatoria intestinal
WO2014174105A1 (en) 2013-04-25 2014-10-30 Philochem Ag Antibody-drug conjugates
WO2014173570A1 (en) 2013-04-26 2014-10-30 Philogen S.P.A. Il4 conjugated to antibodies against extracellular matrix components
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Also Published As

Publication number Publication date
JP5106635B2 (ja) 2012-12-26
US10385121B2 (en) 2019-08-20
AU2008317941A1 (en) 2009-05-07
MX2010004726A (es) 2010-05-20
KR101608544B1 (ko) 2016-04-01
US20190352384A1 (en) 2019-11-21
US9556257B2 (en) 2017-01-31
EP3281952B1 (en) 2020-06-24
JP6198703B2 (ja) 2017-09-20
JP6154594B2 (ja) 2017-06-28
HUE050038T2 (hu) 2020-11-30
KR20160039305A (ko) 2016-04-08
NO2209805T3 (enExample) 2018-02-03
JP2013040183A (ja) 2013-02-28
RU2013115891A (ru) 2014-10-20
KR101836968B1 (ko) 2018-03-12
KR20180027640A (ko) 2018-03-14
BRPI0818272A2 (pt) 2015-04-14
CN103396483A (zh) 2013-11-20
CN101918443A (zh) 2010-12-15
SI3281952T1 (sl) 2020-09-30
CA2704296A1 (en) 2009-05-07
JP2015091799A (ja) 2015-05-14
CA2704296C (en) 2017-08-22
US8222377B2 (en) 2012-07-17
US20120244114A1 (en) 2012-09-27
BRPI0818272B1 (pt) 2021-01-12
ES2807753T3 (es) 2021-02-24
PT2209805T (pt) 2017-11-14
RU2486198C2 (ru) 2013-06-27
EP2209805A1 (en) 2010-07-28
US20170298122A1 (en) 2017-10-19
PL2209805T3 (pl) 2018-01-31
CN101918443B (zh) 2013-07-17
CN103396483B (zh) 2016-11-23
DK2209805T3 (en) 2017-10-16
WO2009056268A1 (en) 2009-05-07
PL3281952T3 (pl) 2020-11-16
EP3281952A1 (en) 2018-02-14
KR102002739B1 (ko) 2019-07-23
US20100260707A1 (en) 2010-10-14
HUE037036T2 (hu) 2018-08-28
RU2010121874A (ru) 2011-12-10
RU2649368C2 (ru) 2018-04-02
BRPI0818272B8 (pt) 2021-05-25
PT3281952T (pt) 2020-07-23
KR20100101587A (ko) 2010-09-17
JP2011502137A (ja) 2011-01-20
EP2209805B1 (en) 2017-09-06
ES2646228T3 (es) 2017-12-12
EP3783019A1 (en) 2021-02-24
SI2209805T1 (sl) 2017-11-30
AU2008317941B2 (en) 2015-01-22

Similar Documents

Publication Publication Date Title
DK3281952T3 (da) Antigen, der er forbundet med reumatoid artritis
CY2019004I1 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
IL257822B (en) Mice that make heavy chain antibodies
DK2196541T3 (da) Anti-glypican-3-antistof med forbedret kinetik i plasmaet
BRPI0819165A2 (pt) Anticorpos anti-vegf
DK2225280T3 (da) Bivalente, bispecifikke antistoffer
BRPI0821405A2 (pt) Anticorpos biespecíficos, bivalentes
BRPI0821375A2 (pt) Anticorpos biespecíficos, bivalentes
BRPI0912260A2 (pt) tonalizador.
DK2131860T3 (da) Anti-sclerostin-antistoffer
PT2195026E (pt) Anticorpos anti-esclerostina
DK2114438T3 (da) Insulinotropisk kompleks, der anvender et immunoglobulin-fragment
DK2207713T3 (da) Fartøjer med rulledæmpningsmekanisme
PL3059246T3 (pl) Zmodyfikowany region stały przeciwciała
BRPI0907532A2 (pt) Anticorpos anti-c5ar humanizados
BRPI0807991A2 (pt) Anticorpos anti-il-23r elaborados.
DK2197900T3 (da) Mutante dobbeltringsluttede receptorpeptider, der inhiberer beta1-adrenoreceptorantistoffer
BRPI0806537A2 (pt) Indazóis substituídos por 5-piridinona
ITMI20071002A1 (it) Manufatto per edilizia.
BRPI0817427A2 (pt) Anticorpo anti-bst2
DK2210105T3 (da) Mycobakterium-antigener
ATE520687T1 (de) 3-amino-6-(1-amino-ethyl)-tetrahydropyranderiva e
BRPI1013157A2 (pt) meio de fixação.
DK2230898T3 (da) Havbrugsnet med forskellige vægtfylder
FR2914820B1 (fr) Boucle auriculaire renforcee.